Arnaud Demange

Preliminary diagnostic performance of [68Ga ]-NeoBOMB1 in patients with gastrin-releasing peptide receptor-positive breast, prostate, colorectal or lung tumors (NeoFIND)

I. Virgolini, F. Orlandi, F. Cortes, 2020 .

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.

E. Mittra, E. Van Cutsem, James C Yao, 2021, The Lancet. Oncology.

Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.

E. Mittra, James C Yao, E. Krenning, 2021 .